From: Ruxolitinib found to cause eyelash growth: a case report
 | Side effects | Treatment |
---|---|---|
Hematologic (dose-related) | Anemia, neutropenia, thrombocytopenia | CBC every 2–4 weeks |
Reduce dose | ||
Blood transfusion for anemia | ||
Dermatologic | Bruising | Â |
Non-melanoma skin cancer (basal, squamous, Merkel) | Periodic skin examination | |
Neurologic | Progressive multifocal encephalopathy | Discontinue ruxolitinib |
Headache | Â | |
Dizziness | Â | |
Endocrine | Hypercholesterolemia, elevated low-density lipoprotein, elevated triglycerides | Assess lipid panel 8–12 weeks after initiation |
Gastrointestinal | Diarrhea | Â |
Limbal | Edema (arm, leg, hand, feet) | Â |
Immunologic | Tuberculosis | Manage tuberculosis |
Herpes zoster | Manage zoster | |
Hepatitis B | Treat hepatitis |